Clinical trials: Dalteparin
Chronic Kidney Failure
Reduction of Heparin Dose in Dialysis With Evodial System
The current clinical study aims at defining an index of Anti Xa, which is the marker to evaluate the activity of heparin, at the end of the dialysis treatment and so showing the possibility to decrease heparin doses during…
- Trial name
- RHODES (NCT00781690)
- Testing
- Evodial hemodialysers and Evodia blood lines
- Where
- 7 sites in France, Germany and 2 more
- Volunteers
- 53 people
- Sponsor
- Vantive Health LLC
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
The primary objective was to compare the efficacy of once daily [q.d.] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP1 (NCT00697099)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 2,326 people
- Sponsor
- Sanofi
Non ST Segment Elevation Myocardial Infarction, Unstable Angina
Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI.
- Trial name
- VECOR (NCT01356992)
- Testing
- Enoxaparin
- Where
- 5 sites in Brazil
- Volunteers
- 62 people
- Sponsor
- Eurofarma Laboratorios S.A.
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin
This clinical study aims to evaluate the efficacy and safety of the anticoagulant Dimolegin® compared to low molecular weight heparin (Clexane®) for the prevention of venous thromboembolic events (VTE) in patients undergoing…
- Conditions
- Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Venous Thromboembolism (VTE), Prevention
- Trial name
- NCT07124819
- Testing
- Sodium enoxaparin, Dimolegin
- Where
- 8 sites in Russia
- Volunteers
- 215 people
- Sponsor
- Avexima Diol LLC
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- ASTER (NCT05171049)
- Testing
- Abelacimab, Apixaban
- Where
- 209 sites in United States, Australia and 19 more
- Volunteers
- 1,150 people
- Sponsor
- Anthos Therapeutics, Inc.
Venous Thromboembolism
Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism
This study is a multicenter post authorization observational study. Cancer patients diagnosed with non high risk VTE and are followed up in an outpatient setting will be treated with LMWH and the data will be recorded.
- Trial name
- TREBECA (NCT02017743)
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Trio Grup Clinical Research
Thrombosis
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
- Trial name
- NCT02981472
- Testing
- Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
- Where
- 46 sites in United States, Argentina and 12 more
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
Thrombosis, Venous
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).
- Trial name
- NCT00312013
- Testing
- Nadroparin
- Where
- 95 sites in Belgium, Canada and 9 more
- Volunteers
- 503 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Chronic Renal Failure
Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure
The primary objective of the study was to assess the safety in use of the drug Heparin Sodium, produced by Cristália Laboratory, compared drug Liquemine ®, manufactured by Roche Laboratory, and secondary purpose was to evaluate…
- Trial name
- heparin (NCT00828776)
- Testing
- Heparin sodic - Cristália, heparin - Liquemine (Roche)
- Where
- Brazil
- Volunteers
- 62 people
- Sponsor
- Azidus Brasil
Metastatic Pancreatic Cancer
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and gemcitabine in combination with an investigational agent called necuparanib (M402).
- Trial name
- NCT01621243
- Testing
- nab-paclitaxel, gemcitabine, Necuparanib
- Where
- 37 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Arthritis, Osteoarthritis, Knee
Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
The study will describe the short-term effects the study drug, rivaroxaban, has on the body when a patient is switched from enoxaparin injection (by needle) to oral rivaroxaban (by mouth) for the prevention of blood clotting in…
- Conditions
- Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
- Trial name
- NCT01094886
- Testing
- Rivaroxaban
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Thromboembolism
A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients
This study is designed to provide efficacy and safety data for certoparin in the prophylaxis of venous thromboembolism in immobilized, acutely ill medical patients.
- Trial name
- NCT00451412
- Testing
- Certoparin, Unfractionated Heparin
- Where
- Germany
- Volunteers
- 3,254 people
- Sponsor
- Novartis
Acute Coronary Syndrome
Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice
To collect data on safety and effectiveness of dalteparin in the management of non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without percutaneous corornary…
- Trial name
- NCT00922766
- Testing
- Dalteparin
- Where
- 24 sites in India
- Volunteers
- 618 people
- Sponsor
- Pfizer
Deep Venous Thrombosis
Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs
The three purposes of this study are the following: To compare during a 6-month treatment the safety and effectiveness of idrabiotaparinux (SSR126517) with that of idraparinux (SR34006), taking into account new events of deep…
- Trial name
- EQUINOX (NCT00311090)
- Testing
- Idrabiotaparinux sodium, Idraparinux sodium, Avidin
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 757 people
- Sponsor
- Sanofi
Angina, Unstable, Myocardial Infarction
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty or bypass surgery)
- Trial name
- NCT00435487
- Testing
- Dalteparin ( Fragmin), Unfractionated heparin
- Where
- 8 sites in India
- Volunteers
- 173 people
- Sponsor
- Pfizer
Malignant Tumor
Evaluation of Fibrin Structure Marker in Cancer Patients Treated and Not Treated With LMWH
The purpose of the study is to assess the fibrin structure marker in the plasma of cancer patients, treated or not treated with LMWH at prophylactic or therapeutic doses, in order to determine the venous thromboembolic risk.
- Trial name
- FICT (NCT02552381)
- Testing
- Fibrin Structure
- Where
- France
- Volunteers
- 389 people
- Sponsor
- Diagnostica Stago R&D
Renal Insufficiency
Study to Assess Bemiparin Pharmacokinetics in Renal Insufficiency and in the Elderly
Open pharmacokinetic study with 5 parallel groups and two treatment phases (bemiparin 3,500 IU multiple dose and bemiparin 115 IU/kg single dose).
- Trial name
- NCT00413088
- Testing
- bemiparin
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
Healthy
Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin
Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
- Trial name
- NCT00618579
- Testing
- LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ThromboGenics
Non Valvular Atrial Fibrillation
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.
- Trial name
- APIXA-Xa (NCT06862726)
- Testing
- Anti Xa dosage, Dosage of PT-INR
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Les Laboratoires des Médicaments Stériles